Evaluation of Treatment Outcomes of Prostate Cancer Patients With Lymph Node Metastasis Treated With Definitive Radiotherapy: Comparative Analysis of PSMA PET/CT and Conventional Imaging
- PMID: 38847441
- DOI: 10.1097/RLU.0000000000005284
Evaluation of Treatment Outcomes of Prostate Cancer Patients With Lymph Node Metastasis Treated With Definitive Radiotherapy: Comparative Analysis of PSMA PET/CT and Conventional Imaging
Abstract
Purpose: We investigated the impact of prostate-specific membrane antigen (PSMA) PET/CT compared with conventional imaging on treatment outcomes for node-positive prostate cancer (PCa) patients who underwent androgen deprivation therapy (ADT) and external radiotherapy (RT).
Patients and methods: A multicentric, retrospective study recruited patients with node-positive PCa patients who underwent conventional radiological evaluation or PSMA PET/CT and received ADT and RT at 3 hospitals from 2009 to 2021 were enrolled. Patients underwent prostate and pelvis RT, accompanied by a minimum of 6 months of ADT. The primary endpoints were progression-free survival (PFS) and PCa-specific survival (PCSS). Cox regression analyzed the association of survival with potential prognostic factors, whereas logistic regression identified the predictors of bone and lymph node metastasis.
Results: The median follow-up time was 64.0 months. The majority of patients (64.1%) underwent PSMA PET/CT for staging. The 5-year rates of PFS and PCSS were 63.7% and 83.7%, respectively. Disease progression was observed in 90 patients (36.3%). In multivariable analysis, ADT duration of less than 24 months and post-RT prostate-specific antigen (PSA) nadir were prognostic for PFS. Early clinical T stage and PSMA PET/CT predicted better PCSS. Patients staged with PSMA PET/CT had exhibited significantly higher 5-year PCSS rates than compared with those staged with conventional imaging (95.1% vs 76.9%; P = 0.01). Shorter ADT duration and higher PSA levels after RT independently predicted bone metastasis in multivariable logistic regression. Advanced T stage, shorter ADT duration, and higher PSA levels after neoadjuvant ADT predicted nonregional lymph node recurrence.
Conclusions: ADT with pelvis RT is an effective treatment option for node-positive PCa patients. The PSMA PET/CT outperformed conventional imaging in PCSS, emphasizing the importance of precise clinical staging for patients undergoing definitive RT.
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
Conflicts of interest and sources of funding: none declared.
Similar articles
-
Optimizing treatment for Gleason 10 prostate cancer: radiation dose escalation and 68Ga-PSMA-PET/CT staging.Strahlenther Onkol. 2025 Aug;201(8):828-836. doi: 10.1007/s00066-025-02376-1. Epub 2025 Feb 28. Strahlenther Onkol. 2025. PMID: 40021524 Free PMC article.
-
Multicenter External Validation and Optimization of a Proposed Nomogram for Prostate-Specific Membrane Antigen PET/CT Accuracy in Biochemical Recurrence.Prostate. 2025 Aug;85(11):1016-1023. doi: 10.1002/pros.24910. Epub 2025 May 6. Prostate. 2025. PMID: 40329523
-
PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging.JAMA Netw Open. 2025 Jan 2;8(1):e2452971. doi: 10.1001/jamanetworkopen.2024.52971. JAMA Netw Open. 2025. PMID: 39752157 Free PMC article.
-
The Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence and Distant Metastases in Patients with Biochemical Recurrence of Prostate Cancer After Definitive Treatment: A Systematic Review and Meta-analysis.Eur Urol. 2025 Aug;88(2):129-141. doi: 10.1016/j.eururo.2025.05.006. Epub 2025 May 19. Eur Urol. 2025. PMID: 40393864 Review.
-
Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard.Eur Urol Oncol. 2022 Feb;5(1):1-17. doi: 10.1016/j.euo.2021.08.001. Epub 2021 Sep 17. Eur Urol Oncol. 2022. PMID: 34538770
Cited by
-
Beyond fluorodeoxyglucose: Molecular imaging of cancer in precision medicine.CA Cancer J Clin. 2025 May-Jun;75(3):226-242. doi: 10.3322/caac.70007. Epub 2025 Apr 4. CA Cancer J Clin. 2025. PMID: 40183513 Free PMC article. Review.
-
Accuracy of dual-contrast gastrointestinal ultrasonography in predicting lymph node metastasis in older adults with gastric cancer.World J Gastrointest Oncol. 2025 May 15;17(5):104194. doi: 10.4251/wjgo.v17.i5.104194. World J Gastrointest Oncol. 2025. PMID: 40487969 Free PMC article.
-
Improved survival of patients with newly diagnosed oligometastatic prostate cancer through intensified multimodal treatment.Front Oncol. 2024 Dec 10;14:1475914. doi: 10.3389/fonc.2024.1475914. eCollection 2024. Front Oncol. 2024. PMID: 39720562 Free PMC article.
References
-
- Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin . 2023;73:17–48.
-
- Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol . 2017;71:618–629.
-
- James ND, Spears MR, Clarke NW, et al. Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial. JAMA Oncol . 2016;2:348–357.
-
- Parker CC, James ND, Brawley CD, et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet . 2018;392:2353–2366.
-
- Lin CC, Gray PJ, Jemal A, et al. Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer. J Natl Cancer Inst . 2015;107:djv119.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous